MedTrace Logo

BTRX-246040 Study in Participants With Parkinson's Disease With Motor Fluctuations

NCT03608371 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2025-06-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and efficacy of BTRX-246040 in participants with Parkinson's Disease who have motor fluctuations and predictable early morning off periods.

Conditions

  • Parkinson Disease
  • Motor Disorder

Interventions

DRUG

BTRX-246040

oral capsule

DRUG

Placebo

oral capsule matching BTRX-246040 capsule

Sponsors & Collaborators

  • BlackThorn Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jane M Tiller, M.D. · BlackThorn Therapeutics, Inc. (Sponsor)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
30 Years
Max Age
76 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-31
Primary Completion
2019-04-16
Completion
2019-04-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03608371 on ClinicalTrials.gov